Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 7/20 | 0.44 |
| ▸ | LGALS9 | O00182 | 3/20 | 0.44 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 3/20 | 0.38 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316862 | 0.86 | LGALS3 (0.48) | LGALS3LGALS9LGALS1LGALS4SLC5A2 | |
| SCHEMBL4787669 | 0.86 | LGALS3 (0.48) | LGALS3LGALS9LGALS1LGALS4SLC5A2 | |
| SCHEMBL3316869 | 0.86 | LGALS3 (0.48) | LGALS3LGALS9LGALS1LGALS4SLC5A2 | |
| SCHEMBL3316874 | 0.86 | LGALS3 (0.48) | LGALS3LGALS9LGALS1LGALS4SLC5A2 | |
| SCHEMBL5215786 | 0.83 | LGALS3 (0.42) | LGALS3LGALS9LGALS1SLC5A2CA1 | |
| SCHEMBL7645733 | 0.83 | LGALS3 (0.42) | LGALS3LGALS9LGALS1SLC5A2CA1 | |
| SCHEMBL8540243 | 0.83 | LGALS3 (0.42) | LGALS3LGALS9LGALS1SLC5A2CA1 | |
| SCHEMBL28182370 | 0.83 | SLC5A2 (0.48) | LGALS9SLC5A2CA1CA2CA12 | |
| SCHEMBL12113492 | 0.82 | LGALS3 (0.41) | LGALS3LGALS9LGALS1LGALS4SLC5A2 | |
| SCHEMBL8540246 | 0.82 | SLC5A2 (0.50) | LGALS9SLC5A2CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815829-B2 | 3′-azido purine nucleotide prodrugs for treatment of viral infections | RFS PHARMA, LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20120135951-A1 | 3'-AZIDO PURINE NUCLEOTIDE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2012-05-31 | — | — | US | disclosed |
| US-20100279969-A1 | AZIDO PURINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | RFS PHARMA, LLC (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279969-A1 | AZIDO PURINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | CDA, APOBEC3G, DIMT1 | LGALS3 2826/4885LGALS9 1240/4885LGALS1 2881/4885 |
| US-20120135951-A1 | 3'-AZIDO PURINE NUCLEOTIDE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS | PNP, ENTPD5, ADA | LGALS3 2463/4885LGALS9 2891/4885LGALS1 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.